Table 6.
Analysis of adverse effects and medication adherence.
| Adverse events | VBQ (n=178) |
VA (n=176) |
VD (n=175) |
P-valuea | P-valueb |
|---|---|---|---|---|---|
| Adverse effects | |||||
| Overall incidence | 36 (20.2%) | 32 (18.2%) | 16 (9.1%) | 0.626 | 0.003 |
| Diarrhea | 4 (2.2%) | 3 (1.7%) | 2 (1.1%) | 0.714 | 0.422 |
| Dizziness | 2 (1.1%) | 3 (1.7%) | 3 (1.7%) | 0.643 | 0.639 |
| Acid reflux/heartburn | 10 (5.6%) | 8 (4.5%) | 2 (1.1%) | 0.646 | 0.020 |
| Nausea/vomiting | 7 (3.9%) | 6 (3.4%) | 6 (3.4%) | 0.794 | 0.802 |
| Abdominal bloating | 11 (6.2%) | 10 (5.7%) | 3 (1.7%) | 0.843 | 0.032 |
| Abdominal pain | 7 (3.9%) | 2 (1.1%) | 1 (0.6%) | 0.095 | 0.034 |
| Rash | 3 (1.7%) | 1 (0.6%) | 0 (0.0%) | 0.320 | 0.085 |
| Bad breath | 2 (1.1%) | 2 (1.1%) | 1 (0.6%) | 1.000 | 0.572 |
| Other | 2 (1.1%) | 4 (2.3%) | 0 (0.0%) | 0.402 | 0.160 |
| Good medication adherence | 172 (96.6%) | 169 (96.0%) | 171 (97.7%) | 0.762 | 0.539 |
a
VA group vs. VBQ group; bVD group vs. VBQ group.
VBQ, vonoprazan-bismuth-amoxicillin-doxycycline quadruple therapy; VA, vonoprazan-amoxicillin dual therapy; VD, vonoprazan-doxycycline dual therapy.